BOUNDLESS BIO, INC. Operating Cash Flow
BOUNDLESS BIO, INC. (BOLD) reported Operating Cash Flow of -$35.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-07
- BOUNDLESS BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$20.97M.
- BOUNDLESS BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$14.97M.
- BOUNDLESS BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$10.11M.
- BOUNDLESS BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$10.20M.
- BOUNDLESS BIO, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$46.66M.
- BOUNDLESS BIO, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$60.84M.
- BOUNDLESS BIO, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$46.85M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$20.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$35.95M 10-Q · filed 2026-08-07 | -$46.05M derived: sum of 3 quarters · filed 2026-08-07 | -$56.25M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$14.97M 10-Q · filed 2026-05-08 | -$25.08M derived: sum of 2 quarters · filed 2026-05-08 | -$35.27M derived: sum of 3 quarters · filed 2026-05-08 | -$47.10M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$10.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$20.30M derived: sum of 2 quarters · filed 2026-03-09 | -$32.13M derived: sum of 3 quarters · filed 2026-08-07 | -$46.66M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$10.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$22.02M derived: sum of 2 quarters · filed 2026-08-07 | -$36.55M 10-Q · filed 2025-11-05 | -$52.12M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$11.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$26.36M 10-Q · filed 2026-08-07 | -$41.92M derived: sum of 3 quarters · filed 2026-08-07 | -$55.19M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$14.53M 10-Q · filed 2026-05-08 | -$30.09M derived: sum of 2 quarters · filed 2026-05-08 | -$43.36M derived: sum of 3 quarters · filed 2026-05-08 | -$59.59M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$15.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$28.83M derived: sum of 2 quarters · filed 2026-03-09 | -$45.06M derived: sum of 3 quarters · filed 2026-03-09 | -$60.84M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$13.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$29.50M derived: sum of 2 quarters · filed 2025-11-05 | -$45.28M 10-Q · filed 2025-11-05 | -$56.96M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$16.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$32.01M 10-Q · filed 2025-08-05 | -$43.70M derived: sum of 3 quarters · filed 2025-08-05 | -$55.89M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$15.78M 10-Q · filed 2025-05-09 | -$27.46M derived: sum of 2 quarters · filed 2025-05-09 | -$39.65M derived: sum of 3 quarters · filed 2025-05-09 | -$50.54M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | -$11.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$23.88M derived: sum of 2 quarters · filed 2025-03-27 | -$34.77M derived: sum of 3 quarters · filed 2025-03-27 | -$46.85M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$12.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$23.08M derived: sum of 2 quarters · filed 2024-11-07 | -$35.17M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$10.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$22.98M 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | -$12.09M 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |